150 related articles for article (PubMed ID: 12060153)
1. Current status of positron emission tomography in oncology.
Scott AM
Australas Radiol; 2002 Jun; 46(2):154-62. PubMed ID: 12060153
[TBL] [Abstract][Full Text] [Related]
2. Current status of positron emission tomography in oncology.
Scott AM
Intern Med J; 2001; 31(1):27-36. PubMed ID: 11478353
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of FDG-PET in oncology.
Czernin J
Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
[TBL] [Abstract][Full Text] [Related]
4. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
5. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (PET) in the evaluation of patients with cancer.
Godwin HA; Zuger JH
Trans Am Clin Climatol Assoc; 1999; 110():181-94. PubMed ID: 10344016
[No Abstract] [Full Text] [Related]
7. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
[TBL] [Abstract][Full Text] [Related]
8. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
[TBL] [Abstract][Full Text] [Related]
9. PET scan imaging in oncology.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Eur J Cancer; 2003 Jul; 39(11):1525-34. PubMed ID: 12855258
[TBL] [Abstract][Full Text] [Related]
10. [The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
Ruiz Hernández G; Romero de Avila Y Avalos C; Carreras Delgado JL
Med Clin (Barc); 2005 Feb; 124(6):229-36. PubMed ID: 15737307
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas.
van der Hiel B; Pauwels EK; Stokkel MP
J Cancer Res Clin Oncol; 2001 May; 127(5):269-77. PubMed ID: 11355141
[TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
Chowdhury FU; Bradley KM; Gleeson FV
Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259
[TBL] [Abstract][Full Text] [Related]
13. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
14. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
[TBL] [Abstract][Full Text] [Related]
15. What does positron emission tomography offer oncology?
Anderson H; Price P
Eur J Cancer; 2000 Oct; 36(16):2028-35. PubMed ID: 11044638
[TBL] [Abstract][Full Text] [Related]
16. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
17. [Use of positron-emission tomography in oncology].
Strauss LG; Kabelitz D; Kremer B; Lode H; Meinertz T; Sauerbruch T; Sterry W
Dtsch Med Wochenschr; 1996 Feb; 121(7):207-9. PubMed ID: 8681765
[No Abstract] [Full Text] [Related]
18. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers.
Rege S; Maass A; Chaiken L; Hoh CK; Choi Y; Lufkin R; Anzai Y; Juillard G; Maddahi J; Phelps ME
Cancer; 1994 Jun; 73(12):3047-58. PubMed ID: 8200003
[TBL] [Abstract][Full Text] [Related]
19. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer.
Yen TC; Ng KK; Ma SY; Chou HH; Tsai CS; Hsueh S; Chang TC; Hong JH; See LC; Lin WJ; Chen JT; Huang KG; Lui KW; Lai CH
J Clin Oncol; 2003 Oct; 21(19):3651-8. PubMed ID: 14512397
[TBL] [Abstract][Full Text] [Related]
20. The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer.
Kutler DI; Wong RJ; Schoder H; Kraus DH
Curr Opin Otolaryngol Head Neck Surg; 2006 Apr; 14(2):73-81. PubMed ID: 16552262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
